Li C, Sun B-Q, Gai X-D
Department of Pathology, School of Basic Medical Sciences, Beihua University, 3999 Huashan Road, Jilin, 132013, People's Republic of China.
Clin Transl Oncol. 2014 Jul;16(7):593-8. doi: 10.1007/s12094-014-1169-7. Epub 2014 Mar 19.
Multidrug resistance (MDR) is a major obstacle to successful cancer chemotherapy. One of the main underlying mechanisms of this resistance is the over-expression of P-glycoprotein (P-gp), an ATP-dependent transmembrane transporter protein encoded by the MDR1 gene. P-gp might transport anti-cancer drugs out of cancer cells and decrease effective intracellular drug concentrations. An effective approach to overcome MDR is to inhibit the function of P-gp or its expression on the surface of cancer cells. Thus, application of MDR reversal agents can be seen as a potentially important means by which to overcome the clinical drug resistance of tumour cells and improve the efficacy of chemotherapy. Recently, research efforts worldwide have focused on reversal mechanisms for MDR and on the identification of reversal agents. Chinese scholars have performed a great deal of exploratory work by screening for efficacy and low toxicity in drug resistance reversal compounds. These compounds may provide more lead compounds with greater activity, leading to the development of more effective therapies for MDR cancer cells. In this review, the function and efficiency of novel compounds derived from traditional Chinese medicines are described.
多药耐药性(MDR)是癌症化疗成功的主要障碍。这种耐药性的主要潜在机制之一是P-糖蛋白(P-gp)的过度表达,P-糖蛋白是一种由MDR1基因编码的ATP依赖性跨膜转运蛋白。P-糖蛋白可能会将抗癌药物转运出癌细胞,并降低细胞内有效药物浓度。克服MDR的一种有效方法是抑制P-糖蛋白的功能或其在癌细胞表面的表达。因此,应用多药耐药逆转剂可被视为克服肿瘤细胞临床耐药性并提高化疗疗效的潜在重要手段。最近,全球的研究工作都集中在MDR的逆转机制和逆转剂的鉴定上。中国学者通过筛选耐药逆转化合物的疗效和低毒性进行了大量探索性工作。这些化合物可能会提供更多活性更高的先导化合物,从而开发出针对MDR癌细胞更有效的治疗方法。在这篇综述中,描述了源自中药的新型化合物的功能和效果。